评估氧尿素在儿科状细胞贫血中的长期益处
Paul E George1, Grace Gardiner Kalmus2, Peter A Lane3
1Emory University School of Medicine, Atlanta, Georgia, United States.
Blood advances
|April 16, 2025
概括
随着时间的推移,尿素显著减少了状细胞贫血 (SCA) 的儿童的急诊和住院治疗. 坚持是最大限度地提高SCA管理中的这些长期临床益处的关键.
科学领域:
- 儿科血液学 儿科血液学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 细胞贫血 (SCA) 管理依赖于氧尿素,但其长期影响和时间效应尚不清楚.
- 了解持续的基尿素疗效对于儿科SCA护理至关重要.
研究的目的:
- 量化素尿素对儿科SCA患者临床和实验室结果的长期影响.
- 分析这些效应在长时间治疗中如何演变.
主要方法:
- 准实验性研究使用差异差异和动态事件研究分析.
- 从2010年到2021年,2,147名患有SCA (HbSS/HbSβ0) 的儿童的纵向队列.
- 主要结局:每年ED访问,住院几天和平均血红蛋白度.
主要成果:
- 基尿素的使用与每年ED访问 (ATT -0.36) 和住院日数 (ATT -0.84) 的持续减少有关.
- 平均血红蛋白度随着氧尿素 (ATT 0.56 g/dL) 的增加,在坚持患者中观察到持续的好处.
- 证明了基尿素在减少小儿SCA的医疗保健利用方面的持续临床益处.
结论:
- 氧尿素为患有SCA的儿童提供了持续的临床益处,减少了多年使用的ED访问和住院.
- 坚持辅导对于优化基尿素在儿科SCA的长期疗效至关重要.
- 该研究为评估其他SCA治疗提供了一个强大的方法框架.
更多相关视频
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
1.7K
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
19.2K
相关概念视频
Bone Marrow Sampling and Transplants
263
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
263
Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Overview of Hematopoiesis
3.6K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
3.6K
iPS Cell Differentiation
2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Role of Hematopoietic Growth Factors
1.2K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.2K
